Yield of next-generation sequencing in diagnostic work up of suspicious biliary strictures

Abstract

Background and study aims

This study addressed the need for improved diagnostic tools to identify malignancy in suspicious biliary strictures. Traditional cytological morphology is often indecisive, prompting exploration of next-generation sequencing (NGS) for enhanced sensitivity. Our aim was to evaluate NGS's additional value in classifying biliary brushes and biopsies and its impact on clinical decision making (CDM).

Patients and methods

In this retrospective single-center cohort study, patients were included from 2019 to 2022 in whom morphologic interpretation and NGS were performed on cytological or histological material from suspicious biliary strictures. Sensitivity and specificity of NGS were calculated for benign or atypical vs. suspicious for malignancy or malignant morphology in biliary brushes and biopsies. In addition, changes in CDM after NGS outcome were evaluated.

Results

In total 109 samples from 106 patients were included in the study. NGS correctly identified 42 of 75 malignancies (56%). Sensitivity and specificity of morphology for brushes were 56% (95% confidence interval [CI] 43%-68%) and 94% (95% CI 79%-99%), respectively. Adding NGS resulted in sensitivity and specificity of 78% (95% CI 66%-87%) and 94% (95% CI 79%-99%). For biopsies, sensitivity and specificity of morphology were 67% (95% CI 35%-90%) and 67% (95% CI 9%-99%) and adding NGS did not alter these results. The outcome of NGS resulted in a change of classification of morphology in 36% and a change in CDM in 8%.

Conclusions

NGS in brushes contributed to more accurate/sensitive diagnoses of malignancy than morphology alone. There was a limited impact on CDM change, but in the future, NGS will undoubtedly play a bigger role when targeted therapy is incorporated in standard treatment and more sensitive NGS panels for cholangiocarcinoma are developed.

Keywords

Pancreatobiliary (ERCP/PTCD) - Strictures - Tissue diagnosis - Diagnostic ERC - GI Pathology

Publication History

Received: 04 March 2025

Accepted after revision: 19 August 2025

Accepted Manuscript online:
20 August 2025

Article published online:
05 September 2025

• References

• 1 Kleeff J, Korc M, Apte M. et al. Pancreatic cancer. Nat Rev Dis Primers 2016; 2: 16022
• 2 Khan SA, Davidson BR, Goldin RD. et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669
• 3 Gerhards MF, Vos P, van Gulik TM. et al. Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg 2001; 88: 48-51
• 4 Clayton RA, Clarke DL, Currie EJ. et al. Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy. Surgeon 2003; 1: 32-38
• 5 Otsuka S, Ebata T, Yokoyama Y. et al. Benign hilar bile duct strictures resected as perihilar cholangiocarcinoma. Br J Surg 2019; 106: 1504-1511
• 6 Govil H, Reddy V, Kluskens L. et al. Brush cytology of the biliary tract: retrospective study of 278 cases with histopathologic correlation. Diagn Cytopathol 2002; 26: 273-277
• 7 Weber A, Schmid RM, Prinz C. Diagnostic approaches for cholangiocarcinoma. World J Gastroenterol 2008; 14: 4131-4136
• 8 Navaneethan U, Njei B, Lourdusamy V. et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015; 81: 168-176
• 9 Burnett AS, Calvert TJ, Chokshi RJ. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature. J Surg Res 2013; 184: 304-311
• 10 Khan J, la Sancha C, Saad M. et al. The role of fluorescence in situ hybridization in pancreatobiliary brushing cytology: A large retrospective review with histologic correlation. Diagnostics (Basel) 2022; 12.
• 11 Mahmoudi N, Enns R, Amar J. et al. Biliary brush cytology: factors associated with positive yields on biliary brush cytology. World J Gastroenterol 2008; 14: 569-573
• 12 Witt BL, Kristen Hilden RN, Scaife C. et al. Identification of factors predictive of malignancy in patients with atypical biliary brushing results obtained via ERCP. Diagn Cytopathol 2013; 41: 682-688
• 13 Okonkwo AM, De Frias DV, Gunn R. et al. Reclassification of "atypical" diagnoses in endoscopic retrograde cholangiopancreaticography-guided biliary brushings. Acta Cytol 2003; 47: 435-442
• 14 Facciorusso A, Crinò SF, Gkolfakis P. et al. Diagnostic work-up of bile duct strictures: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2025; 57: 166-185
• 15 de Jong DM, de Jonge PJF, Stassen PMC. et al. The value of cholangioscopy-guided bite-on-bite (-on bite) biopsies in indeterminate biliary duct strictures. Endoscopy 2025;
• 16 Levy MJ, Baron TH, Clayton AC. et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008; 103: 1263-1273
• 17 Kipp BR, Stadheim LM, Halling SA. et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681
• 18 Zhao B, Zhao B, Chen F. Diagnostic value of serum carbohydrate antigen 19–9 in pancreatic cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2022; 34: 891-904
• 19 Moreno Luna LE, Kipp B, Halling KC. et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-1072
• 20 Navaneethan U, Njei B, Venkatesh PG. et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 943-950 e943
• 21 Kinde I, Wu J, Papadopoulos N. et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108: 9530-9535
• 22 Nikas IP, Mountzios G, Sydney GI. et al. Evaluating pancreatic and biliary neoplasms with small biopsy-based next generation sequencing (NGS): Doing more with less. Cancers (Basel) 2022; 14: 397
• 23 Singhi AD, Nikiforova MN, Chennat J. et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut 2020; 69: 52-61
• 24 Dudley JC, Zheng Z, McDonald T. et al. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. J Mol Diagn 2016; 18: 124-130
• 25 Harbhajanka A, Michael CW, Janaki N. et al. Tiny but mighty: use of next generation sequencing on discarded cytocentrifuged bile duct brushing specimens to increase sensitivity of cytological diagnosis. Mod Pathol 2020; 33: 2019-2025
• 26 van Lier MG, Wagner A, van Leerdam ME. et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med 2010; 14: 181-197
• 27 Pruis MA, Geurts-Giele WRR, von der TJH. et al. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. Lung Cancer 2020; 140: 46-54
• 28 Niederberger M, Spranger J. Delphi technique in health sciences: A map. Front Public Health 2020; 8: 457
• 29 Fritzsche J, Smit E, van Delden O. et al. High sensitivity of biliary brush cytology after optimization of protocol in patients with suspected perihilar or intrahepatic cholangiocarcinoma: a prospective cohort study with historical control. Gastrointest Endosc 2024; 99: AB629-AB630
• 30 Bardhi O, Jones A, Ellis D. et al. Next-generation sequencing improves the detection of malignant biliary strictures and changes management. Gastrointest Endosc 2025; 102: 56-63.e1
• 31 Theisen BK, Wald AI, Singhi AD. Molecular diagnostics in the evaluation of pancreatic cysts. Surg Pathol Clin 2016; 9: 441-456
• 32 Rosenbaum MW, Arpin R, Limbocker J. et al. Cytomorphologic characteristics of next-generation sequencing-positive bile duct brushing specimens. J Am Soc Cytopathol 2020; 9: 520-527
• 33 Kubicka S, Kühnel F, Flemming P. et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001; 48: 403-408
• 34 Kamp E, Dinjens WNM, van Velthuysen MF. et al. Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis. Gastrointest Endosc 2023; 97: 456-465
• 35 Mirallas O, López-Valbuena D, García-Illescas D. et al. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. ESMO Open 2022; 7: 100503
• 36 Proskuriakova E, Khedr A. Current targeted therapy options in the treatment of cholangiocarcinoma: A literature review. Cureus 2022; 14: e26233
• 37 Mosele MF, Westphalen CB, Stenzinger A. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2024; 35: 588-606